Chordate Medical presents interim report for Q2 2022

Chordate Medical Holding (publ) publishes its interim report for Q2 2022 on Tuesday, August 30, 2022, 08:30. On Wednesday, August 31 at 11:00 am, the company invites you to a teleconference with CEO Anders Weilandt.

After the conference, there will be a question-and-answer session. The presentation is held in English. It is possible to follow the conference via computer or mobile devices.

To register for the web conference, register via the following link:

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company's website and on the Västra Hamnen Corporate Finance YouTube channel.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact